@article{4aac2c1cb91543e0bc70f6f595589d54,
title = "Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3",
abstract = "Atrial fibrillation (AF) is a progressive disease, and maintenance of sinus rhythm is cumbersome. In this analysis of the Routine versus Aggressive risk factor driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure (RACE 3) trial we aimed to determine whether optimal treatment of underlying conditions of AF improves maintenance of sinus rhythm in patients with persistent AF and moderate heart failure (HF). Our data showed that optimal treatment of blood pressure, LDL-cholesterol and heart failure was associated with an increase in sinus rhythm maintenance compared to conventional therapy (87% versus 63%, P = .002, respectively).",
keywords = "catheter ablation, trial, TRIAL, CATHETER ABLATION",
author = "B.O. Nguyen and M. Rienstra and A.H. Hobbelt and J.G.P. Tijssen and M.D. Smit and R.G. Tieleman and B. Geelhoed and {Van Veldhuisen}, D.J. and H.J.G.M. Crijns and {Van Gelder}, I.C. and {RACE 3 Investigators}",
note = "Funding Information: Funding: The study is supported by the Netherlands Heart Foundation (Grant 2008B035). Unrestricted grants from AstraZeneca, Bayer, Biotronik, Boehringer-Ingelheim, Boston Scientific, Medtronic, Sanofi-Aventis, St Jude Medical paid to the Netherlands Heart Institute. Dr Tieleman reports grants and personal fees from Bayer, Bristol-Myers-Squibb, Pfizer, and Daiichi-Sankyo. All other authors have no competing interests. Funding Information: Funding: The study is supported by the Netherlands Heart Foundation (Grant 2008B035). Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2020",
month = aug,
day = "1",
doi = "10.1016/j.ahj.2019.12.005",
language = "English",
volume = "226",
pages = "235--239",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Elsevier Inc.",
}